
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 28, 2023, titled "Zydus receives tentative approval from the USFDA for Palbociclib Tablets, 75 mg, 100 mg, and 125 mg".
Filed with NSE ·

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated Jun 28, 2023, titled "Zydus receives tentative approval from the USFDA for Palbociclib Tablets, 75 mg, 100 mg, and 125 mg".
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences